The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

Eli Lilly and Company (NYSE: LLY ) and Verve Therapeutics, Inc. (NASDAQ: VERV ) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

As part of its long-term investment in women’s sports, Eli Lilly will be present at the WNBA All-Star Game through breast ...

Novo Nordisk posted a sharp rise in second-quarter net profit, but rising competition is weighing on sales of its diabetes ...

Eli Lilly and Company (NYSE: LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. An array of pharmaceutical pills with the company’s logo on the bottle.

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.

On July 9, Eli Lilly and Company (NYSE:LLY) reported that the US Food and Drug Administration (FDA) approved a label update with a new recommended titration dosing schedule for Kisunla. Kisunla is ...

$2,700,000 of ELI LILLY AND COMPANY lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.